Trial Profile
Phase I study of vorinostat [suberoylanilide hydroxamic acid (vorinostat)] with irinotecan, 5-fluorouracil (5-FU) and leucovorin (FOLFIRI) for advanced upper gastrointestinal cancers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Vorinostat (Primary)
- Indications Gastric cancer; Liver cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2013 Planned End Date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 27 Mar 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.